Healthcare Industry News: NICOX
News Release - July 17, 2006
Endovasc Cites Favorable Market Conditions for its Liprostin DrugHOUSTON--(HSMN NewsFeed)--July 17, 2006--Endovasc Inc. (OTCBB: EVSC ), cites positive market conditions for its leading drug candidate, Liprostin, for the treatment of intermittent claudication, a symptom of peripheral arterial disease (PAD), leading up to the Company's Phase IIIa trials for the drug. Management points to the failure of competing PAD drug treatments to meet their endpoints in recent clinical trials for its optimistic outlook for Liprostin.
Most recently, Valentis, Inc (NASDAQ: VLTS ) announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in peripheral arterial disease (PAD). In March of this year, Vasogen Inc. (NASDAQ:VSGN ; TSX:VAS ), announced that its Phase III SIMPADICO trial of Celacade for the treatment of PAD failed to meet its endpoint of change in maximal treadmill walking distance. In addition, NICOX S.A, announced in November 2005 the failure of NCX 4016 to meet its primary endpoint for its PAOD trial.
The Company's Phase II trial for Liprostin was successful, with patients showing significant improvements in the primary endpoint of maximum walking distance and pain-free walking distance, a secondary endpoint of the trial. Maximum walking distance of patients enrolled in the trial increased over 100% and the average pain free maximum walking distance increased almost 200%.
"We realize that results from the clinical trials of our competitors have drastically improved the competitive landscape for Liprostin. The recurring theme in these failed trials has been that no existing treatment can increase walking distance in patients with PAD or PAOD. Our site recruitment and budget negotiations are proceeding as planned and we look forward to expanding upon our successful trial results in our upcoming phase IIIa trial," commented Dr. Diane Dottavio, Endovasc's President and CEO.
About Endovasc, Inc.
Endovasc, Inc is focused on developing and commercializing drug candidates in the areas of cardiovascular and metabolic medicine. Endovasc is organized as a business development company, operating through the following subsidiaries: Liprostin Inc., which holds the intellectual property for a liposomal based treatment to increase circulation and reduce leg pain in patients suffering from vascular disease; Prostent, Inc., which is developing urinary tract stent coating technology; and Nutraceutical Development Corporation.
For more information about Endovasc, please visit www.endovasc.com.
Except for the historical information contained herein, this news release contains forward-looking statements that involve risk and uncertainties, including clinical results, the timely availability and acceptance of new products, the impact of competitive products and pricing, the availability of funding from partners or capital markets, and the management of growth, as well as the other risks detailed from time to time in Endovasc's Exchange Commission (SEC) Filings, including the company's Annual Report on Form 10-KSB, and quarterly reports on Form 10-QSB.
Source: Endovasc, Inc.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.